Cover Image
市場調查報告書

PharmaPoint:HER2陰性乳癌:全球藥物預測與市場分析

PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 327649
出版日期 內容資訊 英文 360 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:HER2陰性乳癌:全球藥物預測與市場分析 PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
出版日期: 2015年01月31日 內容資訊: 英文 360 Pages
簡介

本報告提供HER2陰性乳癌概要和治療藥市場收益趨勢、至2023年的預測、開發平台分析、現在及未來的市場競爭趨勢等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
  • 疾病的分類/分期判斷制度
  • 症狀
  • 預後
  • 生活品質

第4章 流行病學

  • 背景
  • 風險係數和共生病症
  • 全球的趨勢
  • 預測方法
  • 乳癌的流行病學的預測:確診發病數量
  • 乳癌的流行病學的預測:確診患病數量
  • 議論

第5章 疾病管理

  • 診斷和治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第6章 競爭評估

  • 概要
  • 產品簡介(品牌治療藥)
  • 產品簡介(荷爾蒙劑)

第7章 未滿足需求和機會

第8章 開發平台評估

第9章 現在及未來加入廠商

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly
    • Pfizer
    • Novartis/GlaxoSmithKline

第10章 市場預測

第11章 附錄

圖表

目錄
Product Code: GDHC92PIDR

Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-negative breast cancer market, with coverage of multiple settings; neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Overall five year survival in breast cancer is relatively high, at around 90%, but this is subjective to the subtype and stage of the disease. Importantly this report segments HER2 negative breast cancer into its two major subtypes; hormone receptor positive (HR+) and triple negative breast cancer (TNBC).

HR+ disease accounts for around 90% of all HER2 negative breast cancers. It responds well to hormonal agents such tamoxifen and the 3rd generation aromatase inhibitors. The advent of hormonal therapy has alleviated some of the unmet needs for these patients, however opportunities still remain. The pipeline for the HR+ market is very strong, with several exciting new agents such as the PI3K and CDK 4/6 inhibitors. GlobalData believes these will have a phenomenal effect on the treatment paradigm for patients with the disease and address many of the unmet needs which patients currently face.

TNBC accounts for around 10% of all HER2 negative breast cancers. TNBC does not respond to hormonal agents and few chemotherapies have been shown to work effectively at managing the disease. The level of unmet need for patients with this form of the disease is very high; furthermore around 30% of TNBC patients will carry a BRCA mutation- these patients have an even worse outcome, with an ultra-high degree of unmet needs. The pipeline for the TNBC market exclusive of the BRCA population is non-existent. However in regards to the BRCA mutation positive market, huge changes are to occur which could potentially redefine the way these patients are treated. This will be chiefly due to the entrance of several PARP inhibitors in the market.

Highlights

Key Questions Answered

  • How is the disease management evolving? What is the impact for drug manufacturers?
  • What are the R&D strategies being used by drug makers?
  • What opportunities remain for future players?
  • How large are the neoadjuvant, adjuvant, and metastatic markets for TNBC and HR+ breast cancer?
  • What exciting, innovative approaches are being investigated in HER2-negative breast cancer?
  • What to KOLs think about the latest therapies and drug development strategies?

Key Findings

  • The HER2-negative breast cancer market will increase by 4-fold; from $1.45 billion in 2013 to $6.12 billion in 2023 at a CAGR of 15.5%. Growth will be driven by the rapid uptake of new premium priced agents in both the HR+ and TNBC settings. Presently the HR + and TNBC settings have around an equal share of the HER2 negative market, by 2023 this is expected to change drastically to around 80% and 20% respectively.
  • In the HR+ setting, the launch of a number of innovative premium-priced products - namely, the PI3K and CDK 4/6 inhibitors, will act as the main drivers for growth. The collective sales from these agents alone will account for $3.6 billion and 79% of the global sales in the HR+ setting in 2023. GlobalData expects Pfizer's Palbociclib to capture sales of $1.85 billion in 2023, making it the highest grossing drug in the HR+ setting and HER2 negative breast cancer as a whole.
  • In the TNBC setting, the launch of several PARP inhibitors will act as the main drivers for growth. The collective sales from all of the PARP inhibitors will account for $1.02 billion and 94% of the global sales in the TNBC setting in 2023. Chief amongst them will be AstraZeneca's Lynparza which will capture sales of $926.3m in 2023.
  • By 2023, the adjuvant setting will prove to be the most lucrative setting in both HR+ and TNBC. Galena Biopharma's NeuVax (nelipepimut-S/E75) will enter the adjuvant setting (HR+) in the US and 5EU; even with relatively low patient shares (<10%), it will score comparatively high global sales of $567m by 2023. AstraZeneca's Lynparza will also enter the adjuvant setting (TNBC), indeed the vast majority of its 2023 sales are expected to come from here 79%; $731m.

Scope

  • Overview of HER2-negative breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized HER2-negative breast cancer therapeutics market revenue, cost of therapy, and treatment usage patterns in 15 patient segments, forecast from 2013 to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HER2-negative breast cancer therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global HER2-negative breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HER2-negative breast cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-negative breast cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Basic Breast Anatomy
  • 3.2. Disease Classification/Staging Systems
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk
    • 4.2.2. Reproductive hormonal factors influence the risk of breast cancer
    • 4.2.3. Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients
    • 4.2.4. Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Prevalence and Survival
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Breast Cancer (2013-2023) - Diagnosed Incident Cases
    • 4.5.1. Diagnosed Incident Cases of Breast Cancer
    • 4.5.2. Diagnosed Incident Cases of Breast Cancer by Age
    • 4.5.3. Diagnosed Incident Cases of Breast Cancer by Menopausal Status
    • 4.5.4. Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis
    • 4.5.5. Age-Standardized Diagnosed Incidence Rate of Breast Cancer
  • 4.6. Epidemiological Forecast for Breast Cancer (2013-2023) - Diagnosed Prevalent Cases
    • 4.6.1. Five-Year Diagnosed Prevalent Cases of Breast Cancer
    • 4.6.2. Five-Year Diagnosed Prevalent Cases by Menopausal Status
    • 4.6.3. Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes
  • 4.7. Discussion
    • 4.7.1. Epidemiological Forecast Insight
    • 4.7.2. Limitations of the Analysis
    • 4.7.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
    • 5.1.2. Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC)
    • 5.1.3. Treatment Guidelines and Leading Prescribed Drugs
  • 5.2. US
    • 5.2.1. Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. China
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles (Branded Therapies)
    • 6.2.1. Abraxane (nab-paclitaxel)
    • 6.2.2. Afinitor (everolimus)
    • 6.2.3. Avastin (bevacizumab)
    • 6.2.4. Doxil/Caelyx (pegylated liposomal doxorubicin)
    • 6.2.5. Halaven (eribulin mesylate)
    • 6.2.6. Ixempra (ixabepilone)
    • 6.2.7. Xeloda (capecitabine)
  • 6.3. Product Profiles (Hormonal Agents)
    • 6.3.1. Tamoxifen
    • 6.3.2. Faslodex (fulvestrant)
    • 6.3.3. Aromatase Inhibitors

7. Unmet Need and Opportunity

  • 7.1. Overview
    • 7.1.1. Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries
    • 7.1.2. Specific treatment options for TNBC patients
    • 7.1.3. Prevention of brain metastasis
    • 7.1.4. Neoadjuvant therapy that can downstage tumors
    • 7.1.5. For HR+patients, reduced resistance to hormonal agents
    • 7.1.6. Improved convenience of administration of hormonal agents

8. Pipeline Assessment

  • 8.1. Overview
    • 8.1.1. Abemaciclib (LY2835219)
    • 8.1.2. Buparlisib (BKM- 120)
    • 8.1.3. Javlor (vinflunine)
    • 8.1.4. LEE011
    • 8.1.5. NeuVax (nelipepimut-S/E75)
    • 8.1.6. Niraparib (MK4827)
    • 8.1.7. NKTR- 102 (etirinotecan pegol)
    • 8.1.8. Lynparza (olaparib)
    • 8.1.9. Palbociclib (PD-0332991)
    • 8.1.10. Talazoparib (BMN 673)
    • 8.1.11. Veliparib (ABT-888)
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. PD-/PD-L 1 Immunotherapies

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. AstraZeneca
    • 9.3.2. Bristol-Myers Squibb
    • 9.3.3. Eli Lilly
    • 9.3.4. Pfizer
    • 9.3.5. Novartis/GlaxoSmithKline

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed HER2-Negative Breast Cancer Patients
    • 11.4.2. Percentage of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - High-Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Director of Oncology
    • 11.7.3. Epidemiologist
    • 11.7.4. Director of Epidemiology
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: AJCC Stage Definitions for Breast Cancer
  • Table 2: Prognosis for Breast Cancer
  • Table 3: Selected Major Risk Factors and Comorbidities for Breast Cancer
  • Table 4: Breast Cancer Mortality Attributable to Lifestyle-Related Risk Factors
  • Table 5: 8MM, Current Status and Plans of Large-Scale Breast Cancer Screening Programs
  • Table 6: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004**
  • Table 7: Conversion of Common Staging Systems for Breast Cancer Used in the Forecast
  • Table 8: 8MM, Sources of the Breast Cancer Diagnosed Incidence Data Used in the Epidemiological Forecast
  • Table 9: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Table 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Age, Women, N (Row %), 2013
  • Table 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N (Row %), 2013
  • Table 12: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013
  • Table 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013
  • Table 15: Treatment Guidelines for HER2-Negative Breast Cancer
  • Table 16: Most Prescribed Regimens for HER2-Negative Breast Cancer by Drug Class in the Global Markets, 2013
  • Table 17: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - US
  • Table 18: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - France
  • Table 19: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - Germany
  • Table 20: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - Italy
  • Table 21: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - Spain
  • Table 22: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - UK
  • Table 23: HER2-Negative Breast Cancer Diagnosis and Treatment Country Profile - Japan
  • Table 24: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile - China
  • Table 25: Product Profile - Abraxane
  • Table 26: Abraxane SWOT Analysis, 2013
  • Table 27: Global Sales Forecast ($m) for Abraxane, 2013-2023
  • Table 28: Product Profile - Afinitor (everolimus)
  • Table 29: Afinitor SWOT Analysis, 2013
  • Table 30: Global Sales Forecast ($m) for Afinitor, 2013-2023
  • Table 31: Product Profile - Avastin
  • Table 32: Avastin SWOT Analysis, 2013

Table 33 Global Sales Forecast ($m) for Avastin, 2013-2023 137

  • Table 34: Product Profile - Doxil
  • Table 35: Doxil SWOT Analysis, 2013
  • Table 36: Global Sales Forecast ($m) for Doxil/Caelyx, 2013-2023
  • Table 37: Product Profile - Halavan
  • Table 38: Halaven SWOT Analysis, 2013
  • Table 39: Global Sales Forecast ($m) for Halaven, 2013-2023
  • Table 40: Product Profile - Ixempra
  • Table 41: Ixempra SWOT Analysis, 2013
  • Table 42: Global Sales Forecast ($m) for Ixempra, 2013-2023
  • Table 43: Product Profile - Xeloda
  • Table 44: Xeloda SWOT Analysis, 2013
  • Table 45: AI Approvals in the US and 5EU
  • Table 46: Unmet Need and Opportunity in HER2-Negative Breast Cancer
  • Table 47: Product Profile - Abemaciclib (LY2835219)
  • Table 48: Abemaciclib SWOT Analysis, 2013
  • Table 49: Global Sales Forecast ($m) for Abemaciclib, 2013-2023
  • Table 50: Product Profile - Buparlisib (BKM- 120)
  • Table 51: Buparlisib SWOT Analysis, 2013
  • Table 52: Global Sales Forecast ($m) for Buparlisib, 2013-2023
  • Table 53: Product Profile - Javlor
  • Table 54: Javlor SWOT Analysis, 2013
  • Table 55: Global Sales Forecast ($m) for Buparlisib, 2013-2023
  • Table 56: Product Profile - LEE011
  • Table 57: LEE011 SWOT Analysis, 2013
  • Table 58: Global Sales Forecast ($m) for LEE011, 2013-2023
  • Table 59: Product Profile - NeuVax
  • Table 60: NeuVax SWOT Analysis, 2013
  • Table 61: Global Sales Forecast ($m) for NeuVax, 2013-2023
  • Table 62: Product Profile - Niraparib
  • Table 63: Niraparib SWOT Analysis, 2013
  • Table 64: Global Sales Forecast ($m) for Niraparib, 2013-2023
  • Table 65: Product Profile - NKTR- 102
  • Table 66: NKTR-102 SWOT Analysis, 2013
  • Table 67: Global Sales Forecast ($m) for NKTR 102, 2013-2023
  • Table 68: Product Profile - Lynparza
  • Table 69: Lynparza SWOT Analysis, 2013
  • Table 70: Global Sales Forecast ($m) for Lynparza, 2013-2023
  • Table 71: Product Profile - Palbociclib
  • Table 72: Palbociclib SWOT Analysis, 2013
  • Table 73: Global Sales Forecast ($m) for Palbociclib, 2013-2023
  • Table 74: Product Profile - Talazoparib
  • Table 75: Talazoparib SWOT Analysis, 2013

Table 76 Global Sales Forecast ($m) for Talazoparib, 2013-2023 219

  • Table 77: Product Profile - Veliparib
  • Table 78: Veliparib SWOT Analysis, 2013
  • Table 79: Global Sales Forecast ($m) for Veliparib, 2013-2023
  • Table 80: Early-Stage Immunotherapies in Development for HER2-Negative Breast Cancer, 2014
  • Table 81: AstraZeneca's, Breast Cancer Portfolio Assessment, 2014
  • Table 82: AstraZeneca SWOT Analysis, 2014
  • Table 83: BMS' Breast Cancer Portfolio Assessment, 2014
  • Table 84: BMS SWOT Analysis, 2014
  • Table 85: Eli Lilly SWOT Analysis, 2014
  • Table 86: Pfizer's Breast Cancer Portfolio Assessment, 2014
  • Table 87: Pfizer SWOT Analysis, 2014
  • Table 88: Novartis' Breast Cancer Portfolio Assessment, 2014
  • Table 89: Novartis SWOT Analysis, 2014
  • Table 90: Global Sales Forecasts ($m) for HER2-Negative Breast Cancer, 2013-2023
  • Table 91: Global HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 92: Sales Forecasts ($m) for HER2-Negative Breast Cancer in the US, 2013-2023
  • Table 93: Key Events Impacting Sales for HER2-Negative Breast Cancer in the US, 2013-2023
  • Table 94: US HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 95: Sales Forecasts ($m) for HER2-Negative Breast Cancer in France, 2013-2023
  • Table 96: Key Events Impacting Sales for HER2-Negative Breast Cancer in France, 2013-2023
  • Table 97: French HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 98: Sales Forecasts ($m) for HER2-Negative Breast Cancer in Germany, 2013-2023
  • Table 99: Key Events Impacting Sales for HER2-Negative Breast Cancer in Germany, 2013-2023
  • Table 100: German HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 101: Sales Forecasts ($m) for HER2-Negative Breast Cancer in Italy, 2013-2023
  • Table 102: Key Events Impacting Sales for HER2-Negative Breast Cancer in Italy, 2013-2023
  • Table 103: Italian HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 104: Sales Forecasts ($m) for HER2-Negative Breast Cancer in Spain, 2013-2023
  • Table 105: Key Events Impacting Sales for HER2-Negative Breast Cancer in Spain, 2013-2023
  • Table 106: Spanish HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 107: Sales Forecasts ($m) for HER2-Negative Breast Cancer in the UK, 2013-2023
  • Table 108: Key Events Impacting Sales for HER2-Negative Breast Cancer in the UK, 2013-2023
  • Table 109: UK HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 110: Sales Forecasts ($m) for HER2-Negative Breast Cancer Japan, 2013-2023
  • Table 111: Key Events Impacting Sales for HER2-Negative Breast Cancer in Japan, 2013-2023
  • Table 112: Japanese HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 113: Sales Forecasts ($m) for HER2-Negative Breast Cancer in China, 2013-2023
  • Table 114: Key Events Impacting Sales for HER2-Negative Breast Cancer in China, 2013-2023
  • Table 115: Chinese HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 116: HER2-Negative Breast Cancer Incidence, 2013-2023
  • Table 117: Key Launch Dates of Marketed and Pipeline Drugs for HER2-Negative Breast Cancer
  • Table 118: Key Expiry Dates of Marketed and Pipeline Drugs Used in HER2-Negative Breast Cancer
  • Table 119: Average Body Weight and Surface Area Across the 8MM
  • Table 120: Cost per Treatment Cycle ($) - Abraxane, Metastatic Setting (HR+)

Table 121 Cost per Treatment Cycle ($) - Avastin, Metastatic Setting (HR+/TNBC) 337

  • Table 122: Cost per Treatment Cycle ($) - Afinitor, Third-Line Hormonal/ Targeted Therapy
  • Table 123: Cost per Treatment Cycle ($) - Doxil, Metastatic Setting (HR+/TNBC)
  • Table 124: Cost per Treatment Cycle ($) - Halaven, Metastatic Setting (HR+/TNBC)
  • Table 125: Cost per Treatment Cycle ($) - Ixempra, Metastatic Setting (HR+/TNBC)

Table 126 Cost per Treatment Cycle ($) - Xeloda, Metastatic Setting (HR+/TNBC) 342

  • Table 127: Cost per Treatment Cycle ($) - Abemaciclib, First-/Second-Line Hormonal/Targeted Metastatic Setting (HR+)
  • Table 128: Cost per Treatment Cycle ($) - Buparlisib, Postmenopausal Hormonal Neoadjuvant, Second- and Third-Line Hormonal/Targeted Metastatic Settings (HR+)
  • Table 129: Cost per Treatment Cycle ($) - Javlor, Third-Line Chemotherapy Metastatic Setting (HR+)
  • Table 130: Cost per Treatment Cycle ($) - LEE011, Postmenopausal Hormonal Neoadjuvan, and First-Line Hormonal/Targeted Metastatic Settings (HR+)
  • Table 131: Cost per Treatment Cycle ($) - NeuVax, Adjuvant Setting (HR+)
  • Table 132: Cost per Treatment Cycle ($) - Niraparib, Metastatic TNBC Setting
  • Table 133: Cost per Treatment Cycle ($) - NKTR-102, Third Line Chemotherapy Metastatic Setting (HR+)
  • Table 134: Cost per Treatment Cycle ($) - Lynparza, Adjuvant and First-Line Metastatic TNBC Settings
  • Table 135: Cost per Treatment Cycle ($) - Palbociclib, First- and Second-Line Hormonal/Targeted Metasatatic Setting (HR+)
  • Table 136: Cost per Treatment Cycle ($) - Talazoparib, Third-Line Metastatic TNBC Setting
  • Table 137: Cost per Treatment Cycle ($) - Veliparib, Neoadjuvant and Second-Line Metastatic TNBC Settings
  • Table 138: Physicians Surveyed by Country

List of Figures

  • Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
  • Figure 2: 8MM, Age-Standardized Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Cases per 100,000 Population, 2008
  • Figure 3: 8MM, Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Rate per 100,000 Population, 2008
  • Figure 4: US, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 1975-2009
  • Figure 5: 5EU, Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Cases per 100,000 Population, 1975-2010
  • Figure 6: Japan, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 2003-2008
  • Figure 7: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004**
  • Figure 8: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Figure 9: 8MM, Diagnosed Incident Cases of Breast Cancer, by Age, Women, N, 2013
  • Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N, 2013
  • Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013
  • Figure 12: 8MM, Age-Standardized Diagnosed Incidence Rate of Breast Cancer, Ages ≥20 Years, Women, Cases per 100,000 Population, 2013
  • Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N, 2013
  • Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013
  • Figure 16: Key Late-Stage Clinical Trials of Abraxane
  • Figure 17: Key Late-Stage Clinical Trials of Afinitor
  • Figure 18: Key Late-Stage Clinical Trials of Avastin
  • Figure 19: Key Late-Stage Clinical Trials of Halaven
  • Figure 20: Late Stage Clinical Trials of Drugs in HR+ Breast Cancer
  • Figure 21: Late Stage Clinical Trials of Drugs in TNBC
  • Figure 22: Key Late-Stage Clinical Trials of Abemaciclib
  • Figure 23: Clinical and Commercial Positioning of Abemaciclib
  • Figure 24: Key Late-Stage Clinical Trials of Buparlisib
  • Figure 25: Clinical and Commercial Positioning of Buparlisib
  • Figure 26: Key Late-Stage Clinical Trials of Javlor
  • Figure 27: Clinical and Commercial Positioning of Javlor
  • Figure 28: Key Late-Stage Clinical Trials of LEE011
  • Figure 29: Clinical and Commercial Positioning of LEE011
  • Figure 30: Key Late-Stage Clinical Trials of NeuVax
  • Figure 31: Clinical and Commercial Positioning of NeuVax
  • Figure 32: Key Late-Stage Clinical Trials of Niraparib
  • Figure 33: Clinical and Commercial Positioning of Niraparib
  • Figure 34: Key Late-Stage Clinical Trials of NKTR-102
  • Figure 35: Clinical and Commercial Positioning of NKTR-102
  • Figure 36: Key Late-Stage Clinical Trials of Lynparza
  • Figure 37: Clinical and Commercial Positioning of Lynparza
  • Figure 38: Key Late-Stage Key Clinical Trials of Palbociclib
  • Figure 39: Clinical and Commercial Positioning of Palbociclib
  • Figure 40: Key Late-Stage Clinical Trials of Talazoparib
  • Figure 41: Clinical and Commercial Positioning of Talazoparib
  • Figure 42: Key Late-Stage Clinical Trials of Veliparib
  • Figure 43: Clinical and Commercial Positioning of Veliparib
  • Figure 44: Global Sales ($m) of Branded Products for HER2-Negative Breast Cancer by Company*, 2013-2023
  • Figure 45: Company Portfolio Gap Analysis in HER2-Negative Breast Cancer 2013-2023
  • Figure 46: Global Sales ($m) for HER2-Negative Breast Cancer by Region, 2013-2023
  • Figure 47: Global Sales for HER2-Negative Breast Cancer by Drug, 2013-2022
  • Figure 48: Sales for HER2-Negative Breast Cancer in the US by Drug, 2013-2022
  • Figure 49: Sales for HER2-Negative Breast Cancer in France by Drug, 2013-2023
  • Figure 50: Sales for HER2-Negative Breast Cancer in Germany by Drug, 2013-2023
  • Figure 51: Sales for HER2-Negative Breast Cancer in Italy by Drug, 2013-2023
  • Figure 52: Sales for HER2-Negative Breast Cancer in Spain by Drug, 2013-2022
  • Figure 53: Sales for HER2-Negative Breast Cancer in the UK by Drug, 2013-2023
  • Figure 54: Sales for HER2-Negative Breast Cancer in Japan by Drug, 2013-2023
  • Figure 55: Sales for HER20Negative Breast Cancer in China by Drug, 2013-2023
Back to Top